Clinical Trials

Atreo & N-SIDE’s Preferred Partnership to Optimize Clinical Trial Ops

Atreo’s Partnership with N-SIDE Integrates Modern RTSM Solutions with Advanced Forecasting Capabilities

Atreo, Inc., a next generation Randomization and Trial Supply Management (RTSM) technology company, has announced a strategic preferred partnership with N-SIDE, a global pioneer in clinical trial optimization through cutting-edge analytics. This collaboration aims to empower pharmaceutical and biotech companies with seamlessly integrated solutions, enabling faster drug development and improved operational efficiency.

As part of the partnership, Atreo’s advanced RTSM platform will integrate with N-SIDE’s innovative Supply App, providing clients with end-to-end visibility, automation, and data-driven decision-making tools for clinical trial management. This synergy will ensure enhanced forecasting, supply chain efficiency, and operational excellence, leading to better outcomes for sites, teams, and, ultimately, patients.

“At Atreo, we’re committed to modernizing how clinical trials are managed by reducing complexity and ensuring agility,” said Ryan Harrison, CEO at Atreo. “Our partnership with N-SIDE aligns perfectly with our mission of delivering ‘Time Better Spent for Clinical Teams, Sites, and Patients.’ Together, we’ll equip our clients with the tools they need to bring life-saving treatments to market faster.”

N-SIDE echoes this enthusiasm. Cyrille Dejemeppe, VP Engineering at N-SIDE, stated, “Our collaboration with Atreo underscores our commitment to leveraging advanced analytics and integrating with modern technology solutions to simplify clinical trial operations. By partnering with Atreo, we are poised to deliver unparalleled value to the clinical trial ecosystem, from forecasting to execution.”

The preferred partnership reflects the shared vision of Atreo and N-SIDE to optimize clinical trial processes while ensuring patient needs remain at the forefront. With this collaboration, sponsors can expect minimized waste, reduced costs, and accelerated timelines—all powered by best-in-class technology and innovation.

For more information about this partnership or to schedule a demo, please contact:

Related posts

BostonGene, NEC and JIP formed Joint Venture in Japan

Business Wire

HealthVerity announced general availability of HealthVerity FLOW 1.1

PR Newswire

Flatiron Health Embarks on Strategic Collaboration with Sanofi

Business Wire